COLO B Coloplast A/S Class B

Coloplast US Named a 2020 Top Workplace

Coloplast US Named a 2020 Top Workplace

The company receives recognition for strong values and company culture. 

Coloplast US announced today that it is included among the Star Tribune’s Top 150 Workplaces in Minnesota. This is the first year the company has made the list, receiving recognition for its commitment to company culture, specifically around trust in leadership, well-informed employees, and strong company values. The company ranked #36 on the list.

The Star Tribune 150 recognizes the most progressive companies in Minnesota based on employee opinions measuring engagement, organizational health and satisfaction. The analysis included responses from more than 76,000 employees at nearly 3,000 Minnesota public, private and nonprofit organizations. Rankings were composite scores calculated purely on the basis of employee responses.

“Our employees are passionate about carrying out our mission of helping people with intimate healthcare needs, so they are able to live their lives with confidence. This recognition helps distinguish Coloplast as an employer of choice for people looking to advance their careers at a fast-growing, closely-knit company that prioritizes trust, collaboration, and open communication,” said Manu Varma, president and SVP of Chronic Care North America.

Star Tribune Publisher Michael J. Klingensmith said, “The companies in the Star Tribune Top 150 Workplaces deserve high praise for creating the very best work environments in the state of Minnesota. My congratulations to each of these exceptional companies.” 

is a medical device company that develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to its users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions.

Coloplast is growing and hiring for many positions. To see current job openings and learn how to join the Coloplast team, visit the company’s .

Contact

Lina Danstrup

Senior Media Relations Manager, Corporate Communications



Attachment

EN
25/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast annoncerer ændringer i ledelsesteamet

Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...

 PRESS RELEASE

Coloplast announces changes to Executive Leadership Team

Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...

 PRESS RELEASE

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...

 PRESS RELEASE

Coloplast A/S - Decisions at the Annual General Meeting 2025

Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...

 PRESS RELEASE

Coloplast A/S - Notice of Annual General Meeting 2025

Coloplast A/S - Notice of Annual General Meeting 2025 Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed.   For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSr. Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSr. Manager, Inve...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch